Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
CRMD Stock Chart & Stats
$11.20
$0.06(0.58%)
At close: 4:00 PM EST
$11.20
$0.06(0.58%)
Day’s Range― - ―
52-Week Range$5.60 - $17.43
Previous CloseN/A
Volume1.29M
Average Volume (3M)2.67M
Market Cap
$912.66M
Enterprise Value$695.76M
Total Cash (Recent Filing)$190.71M
Total Debt (Recent Filing)$435.25K
Price to Earnings (P/E)15.0
Beta1.63
Next Earnings
Nov 06, 2025EPS Estimate
0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding78,340,256
10 Day Avg. Volume2,577,919
30 Day Avg. Volume2,670,221
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)5.63
Price to Sales (P/S)10.97
P/FCF Ratio-9.40
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue5.73
Enterprise Value/Gross Profit5.99
Enterprise Value/Ebitda13.30
Forecast
1Y Price Target
$19.00Price Target Upside69.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Guidance IncreaseCRMD increased its 2025 pro-forma net revenue guidance to at least $375 million, driven by current DefenCath sales and performance of the Melinta portfolio.
Product LaunchRezzayo's launch has looked promising, gaining formulary placement at over 40 health systems and adoption across more than 330 accounts since launch.
Revenue GrowthCRMD reported preliminary third-quarter revenues of at least $100 million, significantly ahead of the Street's $65.9 million, due to stronger than expected DefenCath sales.
Strategic InvestmentCRMD made a $5MM equity investment in Talphera, which is developing Niyad as an anticoagulant, providing CRMD with the first right of negotiation to acquire Talphera.
Bears Say
Market SentimentInvestor caution around the anti-infective space likely resulted in a stock reaction of a decrease in value compared to the market.
Transaction SuccessThe ultimate success of the transaction will hinge on the potential success of the DefenCath total parenteral nutrition (TPN) indication, and the Rezzayo opportunity.
Cormedix News
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $5.60 and its highest was $17.43 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is $912.66M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Nov 06, 2025 which is in 14 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Aug 07, 2025. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.187 by $0.103.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is 0.63.
How many shares outstanding does Cormedix have?
Cormedix has 78,340,256 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of $0.29 in its last earnings report, beating expectations of $0.187. Following the earnings report the stock price went down -9.54%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in CRMD
Cormedix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (69.64% Upside)
$19.00 (69.64% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.97%
12-Months-Change
Fundamentals
Return on Equity
38.35%
Trailing 12-Months
Asset Growth
337.55%
Trailing 12-Months
Company Description
Cormedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company operates in the healthcare sector and its core product is DefenCath, an antibacterial and antifungal solution designed to prevent catheter-related bloodstream infections in patients undergoing hemodialysis.
CRMD Stock 12 Month Forecast
Average Price Target
$19.00
▲(69.64% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―
Ownership Overview
2.16% Insiders
9.11% Mutual Funds
0.51% Other Institutional Investors
76.83% Public Companies and Individual Investors